Novo Nordisk's Semaglutide 7.2 mg Achieves 20.7% Weight Loss in STEP UP Trial, 18.7% Overall in 1,407 Participants

Jan 17, 2025, 12:20 PM

Novo Nordisk A/S announced that its STEP UP trial for semaglutide 7.2 mg demonstrated a primary endpoint achievement with a statistically significant weight loss of 20.7% after 72 weeks of treatment. This result was achieved with treatment adherence among participants, who averaged a weight loss of 20.7%. In cases of broader treatment considerations, the average weight loss was reported at 18.7%. The trial involved 1,407 participants with obesity. In comparison, semaglutide 2.4 mg resulted in a weight loss of 17.5%, while placebo participants lost an average of 2.4%. The STEP UP trial results are positioned against Eli Lilly's Zepbound, which recorded a 23% weight loss over 176 weeks, according to data from August 2024.